RESTON, Va., Nov. 27, 2017 /PRNewswire/ -- Leidos (NYSE: LDOS), a FORTUNE 500 science and information technology company, was awarded a prime contract by the Centers for Disease Control and Prevention (CDC) to provide logistical support, emergency operations, and program coordination to the Division of Strategic National Stockpiles (DSNS). The follow-on single-award time & materials contract has a one year-base period, four one-year options, and a total contract value of $26 million.
The almost $7 billion Strategic National Stockpile (SNS) inventory of antibiotics, medical supplies, antidotes, antitoxins, antiviral, vaccines and other pharmaceuticals requires vigilant monitoring and management to keep stock supplied, rotated, and stored within U.S. Food and Drug Administration potency shelf-life requirements. DSNS requires support for rapid, agile delivery of stockpile material when a national emergency occurs—anywhere, anytime—within the United States or its territories.
Through a 15-year partnership with the CDC on this program, Leidos has developed a well-honed understanding of the DSNS mission to protect the nation's health through responsive key personnel with demonstrated performance, and an ability to adapt and adjust to challenge and priorities. Under the task order, Leidos will continue to augment the DSNS mission by providing trained key personnel with the necessary expertise to provide logistical, technical, operational, and administrative support to assist in operating and maintaining the SNS inventory.
"We look forward to providing the expertise and key personnel necessary to sustain continual improvement to realize goals in logistics, efficiency, and cost reduction strategies that will ultimately allow the DSNS to achieve its mission to be the nation's premier medical materiel preparedness and response organization," said Leidos Group President Jon Scholl.
Leidos is a Fortune 500® science and technology solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $7.04 billion for the fiscal year ended December 30, 2016. For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended December 30, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.
View original content with multimedia:http://www.prnewswire.com/news-releases/centers-for-disease-control-and-prevention-award-leidos-prime-contract-300561998.html